Welcome : Guest

BIOABSORBABLE STENTS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Bioabsorbable Stents in Thousand Units and in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 15 companies including many key and niche players such as -

Abbott Laboratories
Amaranth Medical, Inc.
Arterial Remodeling Technologies SA
BIOTRONIK SE & Co. KG
Elixir Medical Corp.

Click here to request a full list of companies covered in the report...

Code: MCP-6396
Price: $4500
Companies: 15
Pages: 111
Date: January 2015
Market Data Tables: 46
  Status: * New Report



TABLE OF CONTENTS


  BIOABSORBABLE STENTS (Complete Report) Pages : 111   | $4500

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Bioabsorbable Stents – Transforming the Interventional Cardiology Market.....II-11$100
   Evolution of Coronory Stents.....II-21$100
   Global Coronory Stents Market – A Few Key Facts.....II-3
Bioabsorbable Stents Poised to Replace Drug-Eluting Stents in Future.....II-3
1$100
   How are Bioabsorbable Stents Better than Drug-Eluting and Bare Metal Stents.....II-4
Clinical Trial Results Corroborate BVS Therapy.....II-4
1$100
   Market Overview.....II-5 1$100
   Table 1: Bioabsorbable Stents Market Potential: Percentage Share Breakdown of Revenues for Bare Metal Stents, Drug Eluting Stents, and Bioabsorbable Stents (includes corresponding Graph/Chart).....II-6
Current & Future Analysis.....II-6
1$350
   Growth Drivers.....II-7
Absorb® - The First Commercially Available Bioabsorbable Stent.....II-7
Competition - Abbott Leads the Race.....II-7
1$100
   Bioabsorbable Stents in Pipeline: 2013.....II-81$100
   Europe – The Largest Market for Biabsorbable Stents.....II-9
Developing Countries – Hot Spots for Growth.....II-9
1$100
   Market Challenges and Threats.....II-10
Technological Challenges.....II-10
Safety- Efficacy Factor.....II-10
Regulatory Challenges.....II-10
Price Factor.....II-10
1$100
   Alternative Therapies/Devices: Threats to Coronary Stents.....II-11
Cell Transplantation – A Threat to Coronary Stents.....II-11
1$100
   Global Menace of Coronary Artery Disease – A Major Growth Driver.....II-12
Table 2: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart).....II-12

Table 3: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart).....II-12
1$350
   Table 4: Fatalities in Low Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart).....II-131$350
   Table 5: Fatalities in Mid Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart).....II-14

Table 6: Fatalities in High Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD, Cancer, Injury, and Others (includes corresponding Graph/Chart).....II-14
1$350
   Restenosis Creates the Need for Bioabsorbable Stents.....II-15
Ageing Demographics and Longer Life Expectancy Bolsters Market Growth.....II-15
1$100
   Table 7: Global Population Statistics for the 65+ Age Group (2013) (includes corresponding Graph/Chart).....II-161$350
   Table 8: Life Expectancy by Select Countries: 2013 (includes corresponding Graph/Chart).....II-17
Rising Middle Class Population Aids Growth.....II-17
1$350
   Table 9: World Middle Class Population (2012 & 2030F): Percentage Share Breakdown by Region - North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa (includes corresponding Graph/Chart).....II-18
Rising Healthcare Expenditure: Opportunities in Store.....II-18
1$350
   Table 10: Per-Capita Healthcare Expenditure in Select Regions (2013) (includes corresponding Graph/Chart).....II-19

Table 11: Top 20 Countries with the Highest Healthcare Spending as a Percentage of GDP (2012) (includes corresponding Graph/Chart).....II-19
1$350
   Risk of CAD in Obesity Offers Prospects for Coronary Stenting.....II-20 1$100
   Table 12: Global Obese Population in Millions by Region/Country (2013) (includes corresponding Graph/Chart).....II-21

Table 13: Global Obesity Levels (2013): Percentage Share Breakdown of Total Obese Population by Leading Countries (includes corresponding Graph/Chart).....II-21
Diabetics at Higher Risk of Heart Diseases.....II-21
1$350
   Table 14: Worldwide Prevalence of Diabetes Mellitus by Geographic Region (2013 & 2035P) (includes corresponding Graph/Chart).....II-221$350
   The Hypertension-Cholesterol Link to Drive Demand.....II-23
Table 15: Death Rates Due to Hypertension in Select Countries: 2011.....II-23
2$700
   Table 16: Percentage Prevalence Rate of High Blood Pressure for Patients over 25 Years of Age by Region (1980 & 2010) (includes corresponding Graph/Chart).....II-25
Spurt in Medical Tourism Offers Growth Opportunities.....II-25
1$350
   ART Bioabsorbable Stent (Arterial Remodeling Technologies, France).....II-26
DREAMS (BIOTRONIK, Germany).....II-26
DESolve™ Coronary Scaffold (Elixir Medical, US).....II-26
IGAKI-TAMAI® (Kyoto Medical Planning, Japan).....II-26
1$100
   ReZolve® (REVA Medical Inc., US).....II-27
IDEAL (Bioabsorbable Therapeutics, US).....II-27
Magnesium-Based Stent (Luxfer, UK).....II-27
1$100
   LifeTech Iron (LifeTech, China).....II-28
The Xinsorb BRS (Huaan Biotechnology Group, China).....II-28
1$100
   The United States.....II-29
Europe .....II-29
Australia.....II-29
1$100
   Coronary Artery Disease (CAD) - A Perspective.....II-30
Causes and Symptoms.....II-30
Treatment Options for Coronary Artery Disease.....II-30
1$100
   Percutaneous Coronary Intervention (PCI).....II-31
Coronary Stenting.....II-31
Types of Coronary Stents.....II-31
Bare Metal Stents (BMS).....II-31
1$100
   Drug Eluting Stents (DES).....II-32
Bioabsorbable Stents.....II-32
1$100
   Design and Composition of Bioabsorbable Stents.....II-33
Different Types of Bioabsorbable Stents.....II-33
Metallic Bioabsorbable Stents.....II-33
Polymer Bioabsorbable Stents.....II-33
1$100
   Degradation Period of Select Bioabsorbable Materials.....II-34
Challenges.....II-34
1$100
   Other Treatment Options for Coronary Heart Disease.....II-35
Coronary Artery Bypass Grafting (CABG).....II-35
Minimally Invasive Direct Coronary Artery Bypass (MIDCAB).....II-35
TransMyocardial Laser Revascularization (TMR).....II-35
Peripheral Arterial Disease: Understanding the Stealthy Peril.....II-35
1$100
   Treatment for PAD.....II-36
Lifestyle Changes.....II-36
Medication.....II-36
1$100
   Surgery.....II-37
Stenting- A Treatment Option for PAD.....II-37
1$100
   Elixir Receives CE Approval for Bioresorbable Stent.....II-38
Arterial Remodeling Signs Collaboration Agreement with Terumo.....II-38
Abbott Concludes Enrollment for Absorb Clinical Trials for US, China, and
  Japan.....II-38
Abbott Initiates Clinical Trials of ABSORB IV BVS.....II-38
Abbott Initiates Japanese Clinical Trial of Absorb™ BVS.....II-38
Abbott Initiates ABSORB III Clinical Trial in the US.....II-38
1$100
   ART Conducts First-in-Human Clinical Trial of ART Bioabsorbable Stent.....II-39
Kyoto Medical Releases Long-Term Safety and Efficacy Data for its IGAKI-TAMAI®
  Stent.....II-39
Abbott Laboratories Launches Absorb BVS in Europe and Other Markets.....II-39
1$100
   Abbott Laboratories (US).....II-40
Amaranth Medical, Inc. (US).....II-40
Arterial Remodeling Technologies SA (France).....II-40
1$100
   BIOTRONIK SE & Co. KG (Germany).....II-41
Elixir Medical Corp. (US).....II-41
1$100
   Kyoto Medical Planning Co., Ltd. (Japan).....II-42
REVA Medical, Inc. (US).....II-42
1$100
   Unit Sales.....II-43
Table 17: World Current and Future Analysis for Bioabsorbable Stents by Geographic Region - US, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-43
1$350
   Table 18: World 7-Year Perspective for Bioabsorbable Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Europe, Asia-Pacific and Rest of World Markets for Years 2014 and 2020 (includes corresponding Graph/Chart).....II-441$350
   Value Sales.....II-45
Table 19: World Current and Future Analysis for Bioabsorbable Stents by Geographic Region - US, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-45
1$350
   Table 20: World 7-Year Perspective for Bioabsorbable Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific and Rest of World Markets for Years 2014 and 2020 (includes corresponding Graph/Chart).....II-461$350
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Growth Indicators.....III-1
1$75
   Rising CVD Incidence – A Major Growth Driver.....III-2
Table 21: Cardiovascular Disease Incidence in the US by Gender & Age Group (per 1,000 Adults) (includes corresponding Graph/Chart).....III-2

Table 22: Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart).....III-2
1$200
   Ageing Population – A Vital Demography.....III-3
Table 23: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-3
Challenges Ahead.....III-3
1$200
   Strategic Corporate Developments.....III-41$75
   Select Key Players.....III-52$150
   B. Market Analytics.....III-7
Table 24: The US Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-7
1$200
   Table 25: The US Current and Future Analysis for Bioabsorbable Stents with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-81$200
   A. Market Analysis.....III-9
The Largest Market for Bioabsorbable Stent.....III-9
Growth Drivers.....III-9
1$75
   Cardiovascular Disease in Europe – A Perspective.....III-10
Europe - A Highly Diverse Market.....III-10
Absorbable Stents & the Controversies Surrounding Them.....III-10
1$75
   Ageing Population Boosts Demand for Biodegradable Stents.....III-11 1$75
   Table 26: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart).....III-121$200
   Product Launch.....III-13
B. Market Analytics.....III-13
Table 27: European Current and Future Analysis for Bioabsorbable Stents by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-13
1$200
   Table 28: European 7-Year Perspective for Bioabsorbable Stents by Geographic Region - Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2014 and 2020 (includes corresponding Graph/Chart).....III-141$200
   Table 29: European Current and Future Analysis for Bioabsorbable Stents by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-151$200
   Table 30: European 7-Year Perspective for Bioabsorbable Stents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2014 and 2020 (includes corresponding Graph/Chart).....III-161$200
   A. Market Analysis.....III-17
Strategic Corporate Developments.....III-17
Select Player.....III-17
1$75
   B. Market Analytics.....III-18
Table 31: French Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-18
1$200
   Table 32: French Current and Future Analysis for Bioabsorbable Stents with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-191$200
   A. Market Analysis.....III-20
Select Player.....III-20
1$75
   B. Market Analytics.....III-21
Table 33: German Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-21
1$200
   Table 34: German Current and Future Analysis for Bioabsorbable Stents with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-221$200
   Market Analysis.....III-23
Table 35: Italian Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-23
1$200
   Table 36: Italian Current and Future Analysis for Bioabsorbable Stents with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-241$200
   Market Analysis.....III-25
Table 37: The UK Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-25
1$200
   Table 38: The UK Current and Future Analysis for Bioabsorbable Stents with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-261$200
   Market Analysis.....III-27
Table 39: Rest of European Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-27
1$200
   Table 40: Rest of European Current and Future Analysis for Bioabsorbable Stents with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-281$200
   A. Market Analysis.....III-29
The Fastest Growing Market for Bioabsorbable Stents.....III-29
Growth Drivers.....III-29
1$75
   Aging Populace – Potential Opportunities.....III-30
Table 41: Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart).....III-30
Asia-Pacific - A Price Sensitive Market.....III-30
India & China Offer Significant Growth Opportunities.....III-30
1$200
   Table 42: China and India Lead Global Population (July 2013): Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Million) by Age Group (includes corresponding Graph/Chart).....III-31
Focus on Select Markets.....III-31
India.....III-31
A High Potential Market.....III-31
1$200
   Unethical Medical Practices Mar Business Prospects.....III-32
Japan.....III-32
Prospects Weighed down by Regulatory Entanglements.....III-32
Bioabsorbable Stents Status in Japan.....III-32
1$75
   Japanese Coronary Stents Command Higher Prices.....III-33
China.....III-33
Healthcare Reforms to Propel Stent Market.....III-33
Strategic Corporate Development.....III-33
1$75
   Kyoto Medical Planning Co., Ltd. – A Key Player.....III-34
B. Market Analytics.....III-34
Table 43: Asia-Pacific Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-34
1$200
   Table 44: Asia-Pacific Current and Future Analysis for Bioabsorbable Stents with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-351$200
   Market Analysis.....III-36
Table 45: Rest of World Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-36
1$200
   Table 46: Rest of World Current and Future Analysis for Bioabsorbable Stents with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-371$200
  
Total Companies Profiled: 15 (including Divisions/Subsidiaries - 16)

Region/Country Players

The United States 9 Japan 1 Europe 3 France 1 Germany 1 The United Kingdom 1 Asia-Pacific (Excluding Japan) 3
Click here to request a full table of contents and more details on this project.